{"id":11172,"date":"2018-07-27T21:43:08","date_gmt":"2018-07-27T21:43:08","guid":{"rendered":"https:\/\/clone.arsacs.com\/therapeutic-approaches-for-arsacs-dr-benoit-gentil-and-dr-heather-durham\/"},"modified":"2026-03-16T18:09:56","modified_gmt":"2026-03-16T22:09:56","slug":"therapeutic-approaches-for-arsacs-dr-benoit-gentil-and-dr-heather-durham-4","status":"publish","type":"post","link":"https:\/\/arsacs.com\/fr\/therapeutic-approaches-for-arsacs-dr-benoit-gentil-and-dr-heather-durham-4\/","title":{"rendered":"Therapeutic Approaches for ARSACS- Dr. Benoit Gentil and Dr. Heather Durham"},"content":{"rendered":"The current proposal proposes to capitalize on our discoveries and to move forward in two\ndirections. First, pursue the protein\/gene replacement approach until it produces a preclinical proof of\nconcept that includes a translatable delivery method. Second, assess the therapeutic potential of HDAC\ninhibitors for ARSACS. Although not included as a specific aim in this proposal, developments with\nHSP inducers in the ALS study will be applied in the ARSACS models.\n\nDuration: One year\nGrant: $80,000\n\nContacts\n<img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/arsacs.com\/wp-content\/uploads\/2021\/02\/Durham_Benoit_Nov_2017-150x150-2.jpg\" alt=\"\" width=\"150\" height=\"150\" class=\"alignleft size-thumbnail wp-image-3643\">\nDR. Benoit Gentil\nRoom 649, Montreal Neurological Institute\n3801 University street, Montreal, H3A 2B4\nTel: 514-398-8509; Fax: 514-398-1509; email: benoit.gentil@mcgill.ca\n\nDr. Heather Durham\nRoom 649, Montreal Neurological Institute\n3801 University street, Montreal, H3A 2B4\nTel: 514-398-8509; Fax: 514-398-1509; email: heather.durham@mcgill.ca","protected":false},"excerpt":{"rendered":"<p>The current proposal proposes to capitalize on our discoveries and to move forward in two directions. First, pursue the protein\/gene replacement approach until it produces a preclinical proof of concept that includes a translatable delivery method. Second, assess the therapeutic potential of HDAC inhibitors for ARSACS. Although not included as a specific aim in this [&#8230;]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[26],"tags":[],"class_list":["post-11172","post","type-post","status-publish","format-standard","hentry","category-research-2018"],"_links":{"self":[{"href":"https:\/\/arsacs.com\/fr\/wp-json\/wp\/v2\/posts\/11172","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/arsacs.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/arsacs.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/arsacs.com\/fr\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/arsacs.com\/fr\/wp-json\/wp\/v2\/comments?post=11172"}],"version-history":[{"count":1,"href":"https:\/\/arsacs.com\/fr\/wp-json\/wp\/v2\/posts\/11172\/revisions"}],"predecessor-version":[{"id":24401,"href":"https:\/\/arsacs.com\/fr\/wp-json\/wp\/v2\/posts\/11172\/revisions\/24401"}],"wp:attachment":[{"href":"https:\/\/arsacs.com\/fr\/wp-json\/wp\/v2\/media?parent=11172"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/arsacs.com\/fr\/wp-json\/wp\/v2\/categories?post=11172"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/arsacs.com\/fr\/wp-json\/wp\/v2\/tags?post=11172"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}